COMP <GO>
HRMY vs JNJ // GROSS PROFIT MARGIN
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: HRMY 7
— JNJ 5
▲ GROSS PROFIT MARGIN LEADER: HRMY
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
gross-margins
77.20%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 77.20% | 67.90% | +9.30 | HRMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | 25.50% | +37.50 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | 18.5x | -10.70 | HRMY | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | 2.97% | +12.51 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | 34.70% | -10.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 18.30% | 28.50% | -10.20 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 6.00% | +15.50 | HRMY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 5.59 | -0.21 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 62.1 | -11.04 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 23.0x | -11.10 | HRMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $662.49B | -$660.24B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | JNJ REV | HRMY GROSS % | JNJ GROSS % | HRMY FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $94.19B | 77.2% | 67.9% | $347.9M | $19.70B |
| FY 2024 | $714.7M | $88.82B | 78.1% | 69.1% | $218.7M | $19.84B |
| FY 2023 | $582.0M | $85.16B | — | — | $219.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
JNJ // BETA 1.08